First-Line Subcutaneous Mosunetuzumab Shows Encouraging Efficacy, Manageable Safety for Patients With Low Tumor Burden Follicular Lymphoma
According to updated results from the phase 2 Morningsun study, frontline subcutaneous (SC) treatment with fixed-duration mosunetuzumab for patients with low-tumor burden follicular lymphoma (FL) demonstrated efficacy and manageable safety.
These results were presented by John Burke, MD, Rocky Mountain Cancer Centers, Aurora, Colorado, at the 66th ASH Annual Meeting in San Diego, California.
“Mosun SC monotherapy shows encouraging high efficacy as a fixed-duration treatment in first-line low-tumor burden FL. A manageable safety profile was reported, supporting ease of access for patients with drug administration in outpatient settings.”
“Longer follow-up is needed to confirm long-term durability of response and safety,” they added.
Source:
Burke J M, Flinn I W, Budde L E, et al. Fixed-Duration Subcutaneous Mosunetuzumab Is Active and Has a Manageable Safety Profile in Patients with Previously Untreated, Low-Tumor Burden Follicular Lymphoma: Updated Results from the Phase II Morningsun Study. Dec 7-10, 2024; San Diego, CA. Abstract: 3008
